Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Codexis Inc (CDXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,186,819
  • Shares Outstanding, K 54,016
  • Annual Sales, $ 50,020 K
  • Annual Income, $ -23,000 K
  • 36-Month Beta -0.37
  • Price/Sales 16.76
  • Price/Cash Flow N/A
  • Price/Book 21.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.02
  • Number of Estimates 2
  • High Estimate 0.00
  • Low Estimate -0.04
  • Prior Year 0.02
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.40 +33.35%
on 01/24/19
22.49 -2.76%
on 02/13/19
+5.40 (+32.79%)
since 01/22/19
3-Month
15.31 +42.85%
on 12/24/18
23.05 -5.12%
on 12/03/18
+4.45 (+25.55%)
since 11/21/18
52-Week
8.85 +147.12%
on 02/23/18
23.05 -5.12%
on 12/03/18
+12.90 (+143.68%)
since 02/22/18

Most Recent Stories

More News
Codexis to Hold 2018 Fourth Quarter and Full Year Conference Call on February 26

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2018 fourth quarter and full year financial results after market close on Tuesday, February 26, 2019....

CDXS : 21.87 (-0.46%)
Codexis Announces Nestle Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestle Health Science has exercised its option to obtain an exclusive license for the global development and commercialization...

CDXS : 21.87 (-0.46%)
Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan

Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an...

CDXS : 21.87 (-0.46%)
Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a subsidiary. Under the terms of the agreement, Codexis will install certain...

CDXS : 21.87 (-0.46%)
MRK : 80.77 (+1.18%)
Codexis (CDXS) Reports Break-Even Earnings for Q3

Codexis (CDXS) delivered earnings and revenue surprises of 100.00% and 15.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CDXS : 21.87 (-0.46%)
Codexis: 3Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Thursday reported a loss of $2 million in its third quarter.

CDXS : 21.87 (-0.46%)
Codexis Reports Third Quarter 2018 Financial Results

Total revenues increase 70% to $16.9 million driven by higher product revenue and R&D revenue across an increased number of customers

CDXS : 21.87 (-0.46%)
Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114

CDX-6114 meets safety and tolerability endpoints

CDXS : 21.87 (-0.46%)
Codexis to Present at Two Investment Conferences in November

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:

CDXS : 21.87 (-0.46%)
Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CDXS : 21.87 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CDXS with:

Business Summary

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and...

See More

Key Turning Points

2nd Resistance Point 22.49
1st Resistance Point 22.18
Last Price 21.87
1st Support Level 21.70
2nd Support Level 21.53

See More

52-Week High 23.05
Last Price 21.87
Fibonacci 61.8% 17.63
Fibonacci 50% 15.95
Fibonacci 38.2% 14.27
52-Week Low 8.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar